Original Publication Date: 1 July, 2014
Publication / Source: Bioanalysis 6(13)
Authors: Vazvaei F & Garofolo F
The increasing interest in protein therapeutics development has given rise to a concomitant interest in the emerging methodologies for large-molecule (LM) quantification. Even though the ligand-binding assay (LBA) is still the gold-standard for LM quantification, more and more applications are being developed for the bioanalysis of LM by LC–MS, as it often provides certain distinct advantages. Indeed, in certain applications LC–MS does not need high-affinity reagents, and in most cases LC–MS offers a higher dynamic range. Even more, LC–MS has the capacity to allow multiplexing and, in certain cases, offers the opportunity to overcome crossreactivity in LBAs.